WCM/EADO 2021 | The current treatment landscape for MCC
Paul Nghiem, MD, PhD, University of Washington, Seattle, WA, discusses the management of merkel cell caricnoma (MCC) at the WCM/EADO 2021 meeting. Prof. Nghiem gives an overview of the current treatment landscape for MCC, higlighting the use of PD-1 inhibitors in advanced disease and the need to optimize therapy cessation and novel therapies or treatment strategies for the treatment of refractory disease. Prof. Ngheim also outlines the use of neoadjuvant immunotherapy for treatment of MCC. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Paul Nghiem, MD, PhD, has served on an advisory board for EMD Serono and Pfizer and has received institutional research funding to institution from Bristol Myers Squibb and EMD Serono.
